Munich

Medigene Provides Results for Fiscal Year 2019 and Outlook

Thursday, March 26, 2020 - 10:18am

Medigene completed the Phase I/II clinical trial of the DC vaccine in AML patients in December 2019 and reported positive final 2-year topline results in January 2020.

Key Points: 
  • Medigene completed the Phase I/II clinical trial of the DC vaccine in AML patients in December 2019 and reported positive final 2-year topline results in January 2020.
  • These results were consistent with the 12-month interim analysis presented in 2019.
  • Medigene received an upfront payment of US $10 m and is eligible to receive potential development, regulatory, and commercial milestone payments.
  • Prof. Dolores Schendel, CEO/CSO at Medigene AG: In the past fiscal year we set the course for the expansion of our clinical programs.

Sepio Systems Announces Additional Funding to Continue Acceleration of Innovation and Global Expansion

Wednesday, March 25, 2020 - 1:00pm

Following the recent Series A round, Sepio secured an additional $4 million from Munich Re Ventures and Hanaco Ventures, which brings the total investment in the company to $15 million.

Key Points: 
  • Following the recent Series A round, Sepio secured an additional $4 million from Munich Re Ventures and Hanaco Ventures, which brings the total investment in the company to $15 million.
  • We look forward to working with Sepio on growing their market presence and product offering."
  • Sepio will provide a performance guarantee to its customers backed by a subsidiary of Munich Re.
  • "With a new R&D center in Lisbon and our expansion to Europe, with offices opening in the United Kingdom and Germany, Sepio is growing at an exponential rate and this additional funding is fueling that growth.

DGAP-News: 4SC AG provides results for financial year 2019 and outlook

Wednesday, March 25, 2020 - 7:00am

Planegg-Martinsried, Germany, 25 March 2020 - 4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 2019, presenting all material reporting period developments and provides an outlook for 2020.

Key Points: 
  • Planegg-Martinsried, Germany, 25 March 2020 - 4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 2019, presenting all material reporting period developments and provides an outlook for 2020.
  • As of 31 December 2019, 4SC holds cash balance/funds of 45,765 thousand (31 December 2018: 25,036 thousand).
  • For 2020, 4SC is expecting an average monthly use of cash from operations of between 2,200 thousand and 2,600 thousand.
  • 4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs.

Munich Re Life US and the American Cancer Society Join Forces in the Fight Against Cancer

Tuesday, February 18, 2020 - 2:00pm

Munich Re Life US together with the American Cancer Society (ACS) today announced a four-year partnership amplifying both organizations commitment to saving more lives from cancer.

Key Points: 
  • Munich Re Life US together with the American Cancer Society (ACS) today announced a four-year partnership amplifying both organizations commitment to saving more lives from cancer.
  • With this partnership, Munich Re becomes the first company in the reinsurance space to support ACS Research Scholar Grants.
  • Munich Re Life US serves clients throughout the United States from its three locations in New York, Atlanta and Chicago.
  • The American Cancer Society is a global grassroots force of 1.5 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer.

Medigene, IRICoR and Université de Montréal Sign Collaboration and Exclusive Licensing Option on Novel Cancer Antigens

Wednesday, January 29, 2020 - 9:00pm

Additionally, UdeM and IRICoR are eligible to receive development, regulatory and commercial milestone payments, along with tiered royalties, on a per target basis.

Key Points: 
  • Additionally, UdeM and IRICoR are eligible to receive development, regulatory and commercial milestone payments, along with tiered royalties, on a per target basis.
  • Prof. Dolores Schendel, CEO and CSO of Medigene AG: "The goal of immunotherapies is to fight cancer using the immune system.
  • We believe that this cooperation could expand our portfolio with promising, novel targets that are solely expressed in cancer cells.
  • Dr. Nadine Beauger, Chief Executive Officer of IRICoR: IRICoR is delighted to be a part of this new partnership.

BLACKYAK announces Fall/Winter Collection 20/21

Wednesday, January 29, 2020 - 2:00pm

MUNICH, Jan. 29, 2020 /PRNewswire/ -- With the announcement of the Autumn/Winter Collection 20/21, BLACKYAK remains true to itself: innovation, technical perfection and maximum protection from the elements are the ultimate goals.

Key Points: 
  • MUNICH, Jan. 29, 2020 /PRNewswire/ -- With the announcement of the Autumn/Winter Collection 20/21, BLACKYAK remains true to itself: innovation, technical perfection and maximum protection from the elements are the ultimate goals.
  • To protect mountaineers on their missions and provide them with the best possible equipment, BLACKYAK focuses on the development of technical and functional clothing.
  • In order to meet its own product requirements, BLACKYAK installed its own development centre at the company's headquarters in Munich in autumn 2019.
  • For the first time, BLACKYAK is using RECCO technology as a safety feature for buried or injured people in remote areas in its collection.

BLACKYAK announces Fall/Winter Collection 20/21

Wednesday, January 29, 2020 - 11:14am

MUNICH, Jan. 29, 2020 /PRNewswire/ -- With the announcement of the Autumn/Winter Collection 20/21, BLACKYAK remains true to itself: innovation, technical perfection and maximum protection from the elements are the ultimate goals.

Key Points: 
  • MUNICH, Jan. 29, 2020 /PRNewswire/ -- With the announcement of the Autumn/Winter Collection 20/21, BLACKYAK remains true to itself: innovation, technical perfection and maximum protection from the elements are the ultimate goals.
  • To protect mountaineers on their missions and provide them with the best possible equipment, BLACKYAK focuses on the development of technical and functional clothing.
  • In order to meet its own product requirements, BLACKYAK installed its own development centre at the company's headquarters in Munich in autumn 2019.
  • For the first time, BLACKYAK is using RECCO technology as a safety feature for buried or injured people in remote areas in its collection.

ClimatePartner Posts Record Growth and Further Expands Market Presence

Wednesday, January 29, 2020 - 11:20am

MUNICH, Jan. 29, 2020 /PRNewswire/ -- ClimatePartner , the pioneer in climate protection for businesses, reports record growth in 2019 and will further expand its international market presence.

Key Points: 
  • MUNICH, Jan. 29, 2020 /PRNewswire/ -- ClimatePartner , the pioneer in climate protection for businesses, reports record growth in 2019 and will further expand its international market presence.
  • They want to integrate it into their core business, for which they are relying on cooperation with ClimatePartner.
  • Along with this development, ClimatePartner has now increased the number of its employees to approximately 70 a growth of nearly 50 percent compared to the previous year.
  • ClimatePartner offers a wide portfolio of recognised climate protection projects in collaboration with a global partner network.

Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients

Friday, January 10, 2020 - 4:57pm

Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system, affecting mainly adults above 60 years of age.

Key Points: 
  • Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system, affecting mainly adults above 60 years of age.
  • AML is a heterogeneous type of cancer affecting patients blood and bone marrow.
  • However, HSCT induces high morbidity and mortality and only less than half of the AML patients can be treated with HSCT.
  • A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.

Karl Naegler joins Wellington Partners as Managing Partner

Wednesday, January 8, 2020 - 11:03am

MUNICH, Germany, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced that Dr. Karl Naegler joined Wellington as a Managing Partner on January 1, 2020.

Key Points: 
  • MUNICH, Germany, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced that Dr. Karl Naegler joined Wellington as a Managing Partner on January 1, 2020.
  • Regina Hodits, Managing Partner of Wellington Partners, commented: We are very pleased to have Karl joining our leadership team.
  • Karl Naegler, Managing Partner of Wellington Partners, said: I am excited to join such an experienced team with a long-standing track record in life science investments.
  • Wellington Partners is a leading European Venture Capital firm investing in early- and growth stage life science companies.